Oxathiazinane derivatives display both antineoplastic and antibacterial activity: a structure activity study.


Journal

Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060

Informations de publication

Date de publication:
Sep 2023
Historique:
received: 17 02 2023
accepted: 15 04 2023
medline: 31 7 2023
pubmed: 12 5 2023
entrez: 12 5 2023
Statut: ppublish

Résumé

The Oxathiazinane substance class is characterized by a high diversity of chemical structures yet to be fully investigated. Our research group recently proved that the 1.4.5-oxathiazine-4.4-dioxide, known as substance GP-2250, possesses antineoplastic properties as shown on pancreatic carcinoma. This current study aims to gain insights into the structure and activity relationship of a series of different Oxathiazinanes regarding their antineoplastic activity and the potential correlation with antibacterial activity. We investigated the newly synthesized Oxathiazinane derivatives: 2255, 2256, 2287, 2289, 2293 and 2296 in comparison to GP-2250. The antineoplastic effect was evaluated in different cancer entities (breast, skin, pancreas and colon cancer cell lines) by viability, proliferation, and cell migration assays in vitro. Disc diffusion tests were performed on various bacteria strains to examine the antibacterial potential. Additionally, reactive oxygen species (ROS) assays were conducted to investigate mechanistic aspects. The substances GP-2250, 2293, 2289 and 2296 not only showed antineoplastic activity in four different cancer entities but also antibacterial effects, as tested on multiple bacteria strains including MRSA (Methicillin-resistant Staphylococcus aureus). Furthermore, these substances also induced high ROS levels up to 110% in the treated cancer cell lines compared to untreated control cells. These results indicate a correlation between an antineoplastic capacity and antibacterial properties of these derivatives. Both activities appear to be ROS driven. The Oxathiazinane derivatives 2255, 2256 and 2287 lacked both, antineoplastic and antibacterial activity. Thus, a comparable structure activity relationship became apparent for both the antineoplastic and antibacterial activity.

Identifiants

pubmed: 37171614
doi: 10.1007/s00432-023-04799-8
pii: 10.1007/s00432-023-04799-8
pmc: PMC10374762
doi:

Substances chimiques

Reactive Oxygen Species 0
Anti-Bacterial Agents 0
Antineoplastic Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

9071-9083

Informations de copyright

© 2023. The Author(s).

Références

Exp Ther Med. 2014 Dec;8(6):1939-1945
pubmed: 25371760
J Immunol. 2008 Mar 1;180(5):3072-80
pubmed: 18292530
Nat Chem Biol. 2014 Jan;10(1):9-17
pubmed: 24346035
Org Biomol Chem. 2015 Jul 21;13(27):7393-6
pubmed: 26081255
Pharmacol Rev. 2004 Jun;56(2):185-229
pubmed: 15169927
J Antibiot (Tokyo). 2008 Dec;61(12):747-51
pubmed: 19194033
Lancet Infect Dis. 2019 Jan;19(1):56-66
pubmed: 30409683
Annu Rev Genet. 2009;43:67-93
pubmed: 19653858
Chem Biol. 2010 May 28;17(5):421-33
pubmed: 20534341
Trends Microbiol. 2017 Jun;25(6):456-466
pubmed: 28089288
Front Microbiol. 2019 Jul 10;10:1556
pubmed: 31354660
Curr Oncol Rep. 2018 Jun 13;20(8):64
pubmed: 29896642
Cancer Biol Ther. 2010 Jan;9(2):109-10
pubmed: 19949311
Prog Nucleic Acid Res Mol Biol. 1977;20:21-57
pubmed: 71748
Clin Cancer Res. 2013 Aug 15;19(16):4309-14
pubmed: 23719265
FEMS Microbiol Rev. 2013 Nov;37(6):955-89
pubmed: 23802986
EPMA J. 2018 Mar 26;9(2):113-123
pubmed: 29896312
J Nat Prod. 2016 Oct 28;79(10):2731-2739
pubmed: 27736087
Mol Cell. 2007 Jun 8;26(5):675-87
pubmed: 17560373
BMC Cancer. 2017 Mar 24;17(1):216
pubmed: 28340556
Free Radic Biol Med. 2017 Mar;104:144-164
pubmed: 28088622

Auteurs

B Majchrzak-Stiller (B)

Division of Molecular and Clinical Research, Department of General and Visceral Surgery, St. Josef-Hospital, Ruhr-University Bochum, 44791, Bochum, Germany. britta.majchrzak@rub.de.

M Buchholz (M)

Division of Molecular and Clinical Research, Department of General and Visceral Surgery, St. Josef-Hospital, Ruhr-University Bochum, 44791, Bochum, Germany.

I Peters (I)

Division of Molecular and Clinical Research, Department of General and Visceral Surgery, St. Josef-Hospital, Ruhr-University Bochum, 44791, Bochum, Germany.

J Strotmann (J)

Division of Molecular and Clinical Research, Department of General and Visceral Surgery, St. Josef-Hospital, Ruhr-University Bochum, 44791, Bochum, Germany.

J Möhrke (J)

Division of Molecular and Clinical Research, Department of General and Visceral Surgery, St. Josef-Hospital, Ruhr-University Bochum, 44791, Bochum, Germany.

L Zelichowski (L)

Division of Molecular and Clinical Research, Department of General and Visceral Surgery, St. Josef-Hospital, Ruhr-University Bochum, 44791, Bochum, Germany.

L Oehlke (L)

Division of Molecular and Clinical Research, Department of General and Visceral Surgery, St. Josef-Hospital, Ruhr-University Bochum, 44791, Bochum, Germany.

C Quensel (C)

Division of Molecular and Clinical Research, Department of General and Visceral Surgery, St. Josef-Hospital, Ruhr-University Bochum, 44791, Bochum, Germany.

D Fein (D)

Division of Molecular and Clinical Research, Department of General and Visceral Surgery, St. Josef-Hospital, Ruhr-University Bochum, 44791, Bochum, Germany.

P Höhn (P)

Division of Molecular and Clinical Research, Department of General and Visceral Surgery, St. Josef-Hospital, Ruhr-University Bochum, 44791, Bochum, Germany.

T Müller (T)

Geistlich Pharma AG, Wolhusen, Switzerland.

W Uhl (W)

Division of Molecular and Clinical Research, Department of General and Visceral Surgery, St. Josef-Hospital, Ruhr-University Bochum, 44791, Bochum, Germany.

C Braumann (C)

Division of Molecular and Clinical Research, Department of General and Visceral Surgery, St. Josef-Hospital, Ruhr-University Bochum, 44791, Bochum, Germany.
Department of General, Visceral and Vascular Surgery, Evangelische Kliniken Gelsenkirchen, Akademisches Lehrkrankenhaus der Universität Duisburg-Essen, Gelsenkirchen, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH